drugset
drugset / Trial / NCT00003245

Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

NCT00003245 ↗

Phase 2 Completed 50 enrolled M.D. Anderson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of irinotecan in treating patients with recurrent or refractory non-Hodgkin's lymphoma.

Timeline

Start
1998-02-18
Primary completion
2004-07-30
Completion
2004-07-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule — Intravenous

Indications

lymphoma